← Search & browse all drugs
NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics
beclamide
N03AX30
Adult Dosing
- Initial: 500 mg to 1 g daily in divided doses
- Maintenance: 1.5 g to 3 g daily, titrated based on clinical response and tolerability
- Maximum daily dose: 4 g/day
Pediatric Dosing
- Safety and efficacy in pediatric patients not well established
- Children >6 years: Initial 250 mg to 500 mg daily, titrated up to 1.5 g to 2 g daily in divided doses based on weight and response
Indications
- Management of epilepsy (tonic-clonic seizures, partial seizures, and psychomotor epilepsy)
- Adjunctive therapy in refractory seizure disorders
Mechanism of Action
- Derivative of phenylacetic acid acting as an anticonvulsant
- Stabilizes neuronal membranes and suppresses repetitive neuronal firing, likely via voltage-gated sodium channel modulation
Contraindications
- Hypersensitivity to beclamide or other phenylacetic acid derivatives
- Severe hepatic impairment
- Severe renal impairment
- History of drug-induced blood dyscrasias
Adverse Reactions
- Central nervous system: Drowsiness, dizziness, ataxia, headache, confusion, irritability
- Gastrointestinal: Nausea, vomiting, anorexia, abdominal pain
- Hematological: Rare instances of leukopenia, aplastic anemia, agranulocytosis
- Dermatological: Rash, urticaria, pruritus
Drug Interactions
- Central nervous system depressants (alcohol, barbiturates, opioids): Enhances sedative and CNS depressant effects
- Other anticonvulsants (phenytoin, carbamazepine, valproic acid): Potential for pharmacokinetic and pharmacodynamic interactions affecting plasma levels and toxicity
- Hepatotoxic drugs: Increased risk of hepatotoxicity with concurrent use
Curated Content: Needs Vetting Before Put to Clinical Use